Cargando…

Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro

By late 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused tens of millions of infections and over 1 million deaths worldwide. A protective vaccine and more effective therapeutics are urgently needed. We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stone, Nathan E., Jaramillo, Sierra A., Jones, Ashley N., Vazquez, Adam J., Martz, Madison, Versluis, Lora M., Raniere, Marlee O., Nunnally, Haley E., Zarn, Katherine E., Nottingham, Roxanne, Ng, Ken R., Sahl, Jason W., Wagner, David M., Knudsen, Steen, Settles, Erik W., Keim, Paul, French, Christopher T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845641/ https://www.ncbi.nlm.nih.gov/pubmed/33468703 http://dx.doi.org/10.1128/mBio.03495-20

Ejemplares similares

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
por: Zarn, Katherine E., et al.
Publicado: (2022)

Seroconversion to HCoV-NL63 in Rhesus Macaques
por: Dijkman, Ronald, et al.
Publicado: (2009)

Understanding Human Coronavirus HCoV-NL63
por: Abdul-Rasool, Sahar, et al.
Publicado: (2010)

Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
por: Lynch, Sean A., et al.
Publicado: (2021)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Inhibition of HCoV-NL63 infection at early stages of the replication cycle
por: van der Hoek, L., et al.
Publicado: (2006)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry
por: Huang, I-Chueh, et al.
Publicado: (2006)

Atypical HCoV-NL63 Infection in an Infant During the SARS-CoV-2 Pandemic
por: Domouzoglou, Eleni M., et al.
Publicado: (2020)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Solar simulated ultraviolet radiation inactivates HCoV-NL63 and SARS-CoV-2 coronaviruses at environmentally relevant doses
por: Wondrak, Georg T., et al.
Publicado: (2021)

Solar simulated ultraviolet radiation inactivates HCoV-NL63 and SARS-CoV-2 coronaviruses at environmentally relevant doses
por: Wondrak, Georg T., et al.
Publicado: (2021)

Surveillance of endemic human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi, Kenya
por: Otieno, Grieven P., et al.
Publicado: (2020)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2
por: Schirtzinger, Erin E., et al.
Publicado: (2022)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43
por: Mourez, Thomas, et al.
Publicado: (2007)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

HCoV-Oc43–Induced Apoptosis of Murine Neuronal Cells
por: Jacomy, Hélène, et al.
Publicado: (2006)

HCoV-OC43–Induced Encephalitis is in Part Immune-Mediated
por: Butler, Noah, et al.
Publicado: (2006)

Epidemiology of respiratory coronaviruses (HCoV) in a Dutch university hospital
por: Niesters, H.G.M., et al.
Publicado: (2006)

HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic
por: Simula, Elena Rita, et al.
Publicado: (2020)

Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2020)

SARS-CoV-2 Is More Efficient than HCoV-NL63 in Infecting a Small Subpopulation of ACE2+ Human Respiratory Epithelial Cells
por: Castillo, Gino, et al.
Publicado: (2023)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
por: Steiner, Sophie, et al.
Publicado: (2020)

Origins of HIV, HCoV-HKU1, SFTSV, and MERS-CoV and Beyond
por: Liu, Wenli, et al.
Publicado: (2022)

Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo.
por: Ojha, Durbadal, et al.
Publicado: (2023)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
por: Chen, Yongkang, et al.
Publicado: (2022)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
por: Xiang, Jiangchao, et al.
Publicado: (2022)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
por: Dugas, Martin, et al.
Publicado: (2021)

The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection
por: Santacroce, Luigi, et al.
Publicado: (2020)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
por: Feng, Yongmei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gavgkl5vid8mqsksjhj0pebske